Needham analyst James Ricchiuti resumed coverage of Plexus with a Buy rating and a price target of $72 after its Q2 earnings miss and a "disappointing" in-line Q3 EPS guidance, saying that while the stock sold off on the results, he is taking a "more constructive view". The analyst cites an "ongoing momentum in manufacturing wins and the strong outlook for growth over the balance of FY19 in HealthCare/Life Sciences, Aerospace and Defense and Industrial" segments. Ricchiuti adds that Plexus revenues could grow nearly 20% this year, while the outlook for margins should brighten in Q4.